These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9793827)

  • 21. Effects of ddC and AZT on locomotion and acoustic startle. I: Acute effects in female rats.
    Morse DE; Davis HD; Popke EJ; Brown KJ; O'Donoghue VA; Grunberg NE
    Pharmacol Biochem Behav; 1997 Feb; 56(2):221-8. PubMed ID: 9050078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cross-resistance of dideoxycytidine-resistant cell lines to azidothymidine.
    Agarwal RP; Wang W; Yo P; Han T; Fernandez M
    Biochem Pharmacol; 1999 Nov; 58(10):1603-8. PubMed ID: 10535751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy and tolerance of a combination of AZT, DDC, and saquinavir in patients infected with the human immunodeficiency virus].
    Soriano Vázquez V; Rodríguez-Rosado Martínez-Echevarría R; Jiménez-Nacher I; Valencia Ortega E; Moreno Celda V; González-Lahoz J
    Rev Clin Esp; 1998 Sep; 198(9):634-5. PubMed ID: 9803794
    [No Abstract]   [Full Text] [Related]  

  • 24. AZT, ddI, and ddC combinations at FDA advisory hearing. Food and Drug Administration.
    James JS
    AIDS Treat News; 1996 Apr; (no 244):6. PubMed ID: 11363307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro.
    Johnson VA; Merrill DP; Chou TC; Hirsch MS
    J Infect Dis; 1992 Nov; 166(5):1143-6. PubMed ID: 1328402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
    Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L
    N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1.
    Gao Q; Gu Z; Salomon H; Nagai K; Parniak MA; Wainberg MA
    Arch Virol; 1994; 136(1-2):111-22. PubMed ID: 8002779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
    Schapiro JM; Winters MA; Lawrence J; Merigan TC
    AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of efflux proteins by electromagnetic field for delivering azidothymidine and saquinavir into the brain.
    Kuo YC; Lu CH
    Colloids Surf B Biointerfaces; 2012 Mar; 91():291-5. PubMed ID: 22136805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro.
    Hoggard PG; Manion V; Barry MG; Back DJ
    Br J Clin Pharmacol; 1998 Feb; 45(2):164-7. PubMed ID: 9491831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).
    Cohen Stuart JW; Schuurman R; Burger DM; Koopmans PP; Sprenger HG; Juttmann JR; Richter C; Meenhorst PL; Hoetelmans RM; Kroon FP; Bravenboer B; Hamann D; Boucher CA; Borleffs JC
    AIDS; 1999 May; 13(7):F53-8. PubMed ID: 10357371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No tease this time--pros and cons of a long-awaited anti-HIV drug.
    Chang HE
    Posit Aware; 1996; 7(1):18-20. PubMed ID: 11363118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carbovir: the (-) enantiomer is a potent and selective antiviral agent against human immunodeficiency virus in vitro.
    Coates JA; Inggall HJ; Pearson BA; Penn CR; Storer R; Williamson C; Cameron JM
    Antiviral Res; 1991 Feb; 15(2):161-8. PubMed ID: 1677557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy with zidovudine, didanosine and saquinavir.
    Collier AC; Coombs RW; Schoenfeld DA; Bassett R; Baruch A; Corey L
    Antiviral Res; 1996 Jan; 29(1):99. PubMed ID: 8721557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro.
    Gosselin G; Schinazi RF; Sommadossi JP; Mathé C; Bergogne MC; Aubertin AM; Kirn A; Imbach JL
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1292-7. PubMed ID: 8092827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-retroviral therapy in HIV-infected patients: in vitro effects of AZT and saquinavir on the response of CD4 and CD8 lymphocytes to interleukin-7.
    Beq S; Bugault F; Colle JH; Lambotte O; Delfraissy JF; Thèze J
    Eur Cytokine Netw; 2005 Dec; 16(4):293-9. PubMed ID: 16464744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection.
    Pizzo PA; Butler K; Balis F; Brouwers E; Hawkins M; Eddy J; Einloth M; Falloon J; Husson R; Jarosinski P
    J Pediatr; 1990 Nov; 117(5):799-808. PubMed ID: 2172501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro anti-human immunodeficiency virus and anti-hepatitis B virus activities and pharmacokinetic properties of heterodinucleoside phosphates containing AZT or ddC.
    Peghini PA; Zahner R; Kuster H; Schott H; Schwendener RA
    Antivir Chem Chemother; 1998 Mar; 9(2):117-26. PubMed ID: 9875383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.